The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Breast Cancer in Men

Sharon H. Giordano, MD; Aman U. Buzdar, MD; and Gabriel N. Hortobagyi, MD
[+] Article, Author, and Disclosure Information

From the University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Grant Support: In part by the Nellie B. Connally Breast Cancer Research Fund.

Requests for Single Reprints: Sharon H. Giordano, MD, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030; e-mail, sgiordano@mdanderson.org.

Current Author Addresses: Drs. Giordano, Buzdar, and Hortobagyi: The University of Texas M.D. Anderson Cancer Center, Department of Breast Medical Oncology, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030.

Ann Intern Med. 2002;137(8):678-687. doi:10.7326/0003-4819-137-8-200210150-00013
Text Size: A A A

Purpose: Breast cancer in men is uncommon; 1500 new cases are diagnosed in the United States yearly. Optimal management of breast cancer in men is unknown because the rarity of the disease precludes large randomized trials. A review of the literature was undertaken with emphasis on articles published over a 10-year period.

Data Sources: Articles published between 1942 and 2000 on breast cancer in men were identified by using CancerLit, MEDLINE, and study bibliographies.

Study Selection: All retrospective series and studies focusing on the epidemiology, risk factors, genetics, and pathology of breast cancer in men.

Data Extraction: Data on the epidemiology, risk factors, genetics, pathology, molecular markers, prognostic factors, therapy, and outcomes of breast cancer in men.

Data Synthesis: Carcinoma of the male breast accounts for 0.8% of all breast cancers. Risk factors include testicular disease, benign breast conditions, age, Jewish ancestry, family history, and the Klinefelter syndrome. BRCA2 mutations predispose men to breast cancer and may account for 4% to 14% of all cases. Pathology data were reviewed: 81% of tumors were estrogen receptor positive, 74% were progesterone receptor positive, 37% overexpressed c-erbB-2, 30% overexpressed p53, 79% overexpressed Bcl-2, 51% overexpressed cyclin D1, and 39% overexpressed epidermal growth factor receptor. Prognostic factors include tumor size, histologic grade, and lymph node status; survival is similar to that of breast cancer in women when patients are matched for age and stage. Adjuvant hormonal therapy and chemotherapy, using the same guidelines as for women, are recommended for men. Hormonal therapy is the primary therapy for metastatic disease; chemotherapy should be reserved for hormone-refractory disease.

Conclusion: Breast cancer is similar in men and women; however, breast cancer in men is more frequently hormone receptor positive and may be more sensitive to hormonal therapy.


Grahic Jump Location
Treatment recommendations for breast cancer in men.

CT = computed tomography; GnRH = gonadotropin-releasing hormone.

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Breast Cancer in Men

The summary below is from the full report titled “Breast Cancer in Men.” It is in the 15 October 2002 issue of Annals of Internal Medicine (volume 137, pages 678-687. The authors are SH Giordano, AU Buzdar, and GN Hortobagyi.


Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.